Now maybe Sarissa will have something to work with....
Amarin and CSL Seqirus Announce Exclusive License and Distribution Agreement to Commercialize VAZKEPA® (Icosapent Ethyl) in Australia and New Zealand
GLOBENEWSWIRE 8:00 AM ET 2/28/2023
Symbol Last Price Change
AMRN 1.84up 0 (0%)
CMXHF 198.976down 0 (0%)
QUOTES AS OF 04:00:00 PM ET 02/27/2023
DUBLIN, Ireland and BRIDGEWATER, N.J. and MELBOURNE, Australia, Feb. 28, 2023 (GLOBE NEWSWIRE) -- Amarin Corporation plc(AMRN) and CSL Seqirus today announced that the two companies have entered into an exclusive license and distribution agreement under which Amarin(AMRN) will license exclusive rights to VAZKEPA to CSL Seqirus to secure pricing and reimbursement and commercialize the product across Australia and New Zealand.
"We are excited to announce this agreement with CSL Seqirus in Australia and New Zealand, a world-class licensing partner for pharmaceuticals,” said Karim Mikhail, President & CEO, Amarin(AMRN). “CSL Seqirus’ highly experienced market access and commercialization teams in Australia and New Zealand are well-positioned to support the pricing and reimbursement efforts, particularly with their strong record in successfully supporting pharmaceutical benefits listings, and eventual marketing and promotion for VAZKEPA and help us to deliver this important medicine to patients in these countries."
According to the Australian Institute of Health and Welfare (AIHW), approximately 1.3 million patients in Australia have established cardiovascular disease (CVD)i and approximately 75% are currently treated with a statin.ii CVD and diabetes are health priorities in NZ. Maori and Pacific peoples have a high incidence of CVD and diabetes and experience significant inequity in both access to medicines and clinical outcomes.
Under the terms of the agreement, CSL Seqirus will in-license VAZKEPA from Amarin(AMRN) and will be responsible for market access and reimbursement efforts, distribution, and commercial promotion for VAZKEPA across Australia and New Zealand. Amarin(AMRN) will receive an upfront payment and be eligible for event-related milestone payments of up to approximately $8 million and additional product-related milestone payments of up to approximately $4 million. Amarin(AMRN) will be responsible for supplying finished product to CSL Seqirus at a profitable transfer price paid to Amarin(AMRN).
About Amarin(AMRN)
Amarin (AMRN) is an innovative pharmaceutical company leading a new paradigm in cardiovascular disease management. From our foundation in scientific research to our focus on clinical trials, and now our commercial expansion, we are evolving and growing rapidly. Amarin(AMRN) has offices in Bridgewater, New Jersey in the United States, Dublin in Ireland, Zug in Switzerland, and other countries in Europe as well as commercial partners and
